Provider and Caregiver Connection™: Patient Perspectives in EGPA: Perfecting the Differential Diagnosis

Released On
January 30, 2020

Expires On
January 30, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Allergy & Immunology, Primary Care, Pulmonology, Rheumatology

 

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

 

Supported by an educational grant from GlaxoSmithKline.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for primary care physicians, rheumatologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with eosinophil granulomatosis with polyangiitis (EGPA).

Program Overview

Provider and Caregiver Connection™: Patient Perspectives in Eosinophil Granulomatosis With Polyangiitis is an online activity featuring a clinical discussion of the latest advances in caring for patients diagnosed with eosinophil granulomatosis with polyangiitis (EGPA), which is complemented by commentary from a patient diagnosed with this disease who shares perspectives and personal experiences. By participating in this activity, you will gain knowledge of the most recent clinical advances in EGPA therapies, including information regarding the diagnosis, treatment, and management strategies for patients diagnosed with this disease, and have a unique opportunity to learn about a patient’s journey with EGPA.

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

  • Evaluate recommendations for early assessment and diagnosis for patients with EGPA.
  • Discuss relevant patient insights and strategies to improve the collaborative care. approach for patients with EGPA.
  • Assess disease progression to properly screen for and diagnose EGPA.
  • Develop an individualized management plan for patients with EGPA.

Faculty

Michael E. Wechsler, MD

Professor of Medicine
Director, Asthma Program
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO

Robin M. Lingg LaGrone, RN, BSN

Registered Nurse
Department of Pulmonology
National Jewish Health
Denver, CO

Anne Tournay, MD (Patient Interviewee)

Physician Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians

Physician Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Disclosures of Conflicts of Interest

Michael E. Wechsler, MD

  • Grant/Research Support: AstraZeneca, Sanofi, Regeneron, Teva
  • Consultant: AstraZeneca, Equillium, GSK, Novartis, Regeneron, Sanofi, Teva.

Robin M. Lingg LaGrone, RN, BSN

  • No relevant financial relationships with commercial interests to disclose.

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Disclosure of Unlabeled Use

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.